Uncategorized

Angelini inks $4.1B Catalyst buy to enter US rare disease market

Published

on

Catalyst Pharmaceuticals comes with a trio of approved drugs as Angelini Pharma expands its neuroscience offerings.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version